36
Participants
Start Date
August 29, 2025
Primary Completion Date
August 31, 2027
Study Completion Date
August 31, 2027
Placebo (Sterile Saline or Balanced Salt Solution)
A control 50 μl injection of clear sterile saline or balanced salt solution (BSS) liquid.
100 μg KIO-301
KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
50 μg KIO-301
KIO-301 drug product is an ophthalmic formulation of the drug substance KIO-300-Cl in sulfobutylether-β-cyclodextrin, sucrose, phosphate buffer salts and water suitable for IVT injection. The drug substance KIO-300-Cl is a quaternary ammonium chloride salt of the active compound KIO-300.
RECRUITING
Save Sight Institute, Sydney
RECRUITING
Cerulea Clinical Trials, East Melbourne
RECRUITING
Queensland Eye Institute, Woolloongabba
NOT_YET_RECRUITING
Royal Adelaide Hospital, Adelaide
RECRUITING
Lions Eye Institute, Nedlands
Lead Sponsor
Kiora Pharmaceuticals, Inc.
INDUSTRY